FDA Clearance Tracker · P240024-S002
Genio® System 2.1
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Nov 6, 2025
Approved
Time to decision
62 days
Received Sep 5, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240024-S002
- Device name
- Genio® System 2.1
- Applicant
- Nyxoah S.A.
- Applicant location
- Mont-Saint-Guibert
- Received
- Sep 5, 2025
- Decided
- Nov 6, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240024
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240024.
Source documents
Other decisions for Nyxoah S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240024 · Decided Aug 8, 2025 · 403 days after receipt
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.